HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of chronic lymphocytic leukemia and lymphosarcoma with a new chlorambucil ester of prednisolone (Leo 1031) (NSC-134087).

Abstract
A new chlorambucil ester of prednisolone (LEO 1031) has been evaluated in patients with advanced lymphocytic lymphosarcoma and chronic lymphocytic leukemia. All 11 patients had been previously treated with radiotherapy and/or combination chemotherapy. Three complete remissions and one partial remission were seen in 4/7 lymphocytic lymphosarcoma patients treated with LEO 1031. In the chronic lymphocytic leukemia group, 3/4 have had benefit. This new drug is considered worthy of further trial.
AuthorsC W Aungst, A Mittelman, G P Murphy
JournalJournal of surgical oncology (J Surg Oncol) Vol. 7 Issue 6 Pg. 457-60 ( 1975) ISSN: 0022-4790 [Print] United States
PMID1102806 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Chlorambucil
  • Prednisolone
Topics
  • Chlorambucil (analogs & derivatives, therapeutic use)
  • Clinical Trials as Topic
  • Female
  • Humans
  • Leukemia, Lymphoid (drug therapy)
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Prednisolone (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: